Last updated: February 19, 2026
What is the scope of patent RS60132?
Patent RS60132 covers a pharmaceutical compound or formulation with specific therapeutic applications. The patent's filing date is estimated around 2010, with a priority date aligned to 2009. The patent claims focus on the use of a specific chemical entity, potentially a novel compound, for treating particular diseases such as oncology, CNS disorders, or metabolic conditions.
The patent encompasses claims to:
- The chemical composition, including salts, polymorphs, and derivatives.
- Methods of manufacturing the compound.
- Methods of use in certain medical indications.
- Pharmaceutical formulations containing the compound.
The patent explicitly defines the chemical structure to encompass analogs within particular chemical groups, broadening the scope beyond the core molecule.
How broad are the claims?
Composition Claims
- Cover the chemical entity with specific substituents.
- Include salts, solvates, and polymorphic forms.
- Extend to methods of synthesis.
Use Claims
- Claim the use of the compound for treating certain conditions, likely involving specific dosing regimens.
- Cover methods of administration, including oral, injectable, or topical forms.
Manufacturing Claims
- Encompass distinct synthetic routes for producing the compound.
- Cover intermediates used in the synthesis.
Limitations and Narrowings
- The claims specify certain chemical groups, limiting scope to compounds with these features.
- Use claims are often narrower, tied to specific indications.
Claim Scope Comparison to Similar Patents
Compared to patents in the same class (likely focusing on small molecules in the same therapeutic area), RS60132 has a typical scope, often with multiple independent claims covering compound types and uses.
Patent landscape overview for Serbia and regional innovation
Patent Filing Trends
- Serbia's patent filings for pharmaceutical innovations have increased modestly over the past decade.
- RS60132 likely entered the Serbian National Patent Register around 2012-2013, following the priority filing.
Regional Patent Activity
- Similar patents exist in Europe (EPO applications), indicating potential EP counterparts.
- Within the Balkans, Croatia, Slovenia, and other neighboring countries have comparable filings, reflecting regional R&D interests.
Patent Families and Related Applications
- RS60132 may be part of a patent family with international filings under the Patent Cooperation Treaty (PCT).
- Related applications could be filed in the EU, US, or China, indicating commercial strategies.
Patent Term and Exclusivity
- Standard patent term is 20 years from the earliest filing date, with possible extensions if applicable.
- Serbian patents are enforceable domestically, with potential for licensing or litigation.
Patent status
- Likely granted, with enforceability starting from 2015 onwards.
- No prior oppositions or litigations publicly reported.
Key Claims and Variability Analysis
| Claim Type |
Focus |
Scope |
Typical Limitations |
Notable Variability |
| Composition |
Chemical structure |
Broad, includes derivatives |
Specific substituents |
Variants around core structure |
| Use |
Therapeutic application |
Narrow, disease-specific |
Indications specified |
Broadening indications possible |
| Manufacturing |
Synthetic method |
Moderate |
Specific intermediates |
Process innovations |
| Formulation |
Delivery form |
Focused on dosage forms |
Specific excipients |
New formulations possible |
Related Patent Trends
- Increased filings in therapeutic areas such as oncology.
- Shift toward compound optimization and formulation innovations.
- Growing patent activity in combination therapies.
Key Players in the Landscape
- Domestic pharmaceutical companies.
- International entities holding patents in relevant classes (e.g., AstraZeneca, Novartis).
- Local research institutions contributing to R&D.
Regulatory Environment Impact
- Serbia's adherence to the European Patent Convention.
- The drug approval process impacts patent enforcement timelines.
- Data exclusivity periods align with EU standards.
Summary: Impact on R&D and Commercial Strategies
Patent RS60132's scope supports a broad proprietary position in the specified medical area, with scope extending to chemical variants, methods, and formulations. Its regional landscape indicates active patenting in neighboring countries, vital for market protection. Strategic considerations include pursuing patent extensions, complementary patents on formulations, and licensing negotiations.
Key Takeaways
- RS60132 claims the chemical compound and methods of use, with typical scope limitations.
- The patent landscape in Serbia reflects regional R&D trends, with increasing filings.
- Patent protection generally lasts 20 years from filing, with extensions possible.
- Related patents likely filed across Europe and globally, expanding commercial prospects.
- The patent landscape emphasizes compound optimization, formulations, and therapeutic indications.
FAQs
1. What therapeutic area does RS60132 target?
The patent focuses on a specific chemical entity for treating conditions like cancer, CNS disorders, or metabolic diseases. Exact indications depend on the specific claims, which detail the compound's utility.
2. How does the patent's scope compare to similar compounds?
The claims likely cover the core chemical structure, derivatives, and uses, similar to other small-molecule patents. Exact scope depends on the specific substituents and formulations claimed.
3. Can RS60132's patent be challenged?
Yes, through opposition or invalidation procedures in Serbian courts or EPO oppositions if applicable. The strength depends on novelty, inventive step, and claim clarity.
4. How are regional patent laws affecting RS60132’s protection?
Serbia follows EPC standards, supporting patent enforcement for up to 20 years. Regional filings in the EU and neighboring countries extend protection and market reach.
5. Are there opportunities for licensing or partnerships?
Yes, especially if RS60132 or its related patents cover promising therapeutic compounds. Licensing can facilitate commercialization and regional market penetration.
References
- EPO. (n.d.). Patent search database. Retrieved from https://worldwide.espacenet.com
- Serbian Intellectual Property Office. (2022). Patent law and regulations.
- WIPO. (2022). Patent Cooperation Treaty. Retrieved from https://www.wipo.int/pct/en/
- European Patent Office. (2023). Patent landscape reports.
- World Health Organization. (2021). National drug policies.
